Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma.
| Revenue (Most Recent Fiscal Year) | $313.90M |
| Net Income (Most Recent Fiscal Year) | $-20.21M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.73 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.73 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -39.87% |
| Net Margin (Trailing 12 Months) | -41.79% |
| Return on Equity (Trailing 12 Months) | -16.06% |
| Return on Assets (Trailing 12 Months) | -12.40% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.21 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.05 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.22 |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.11 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.30 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.31 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.95 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Common Shares Outstanding | 49.74M |
| Free Float | 49.45M |
| Market Capitalization | $1.32B |
| Average Volume (Last 20 Days) | 1.20M |
| Beta (Past 60 Months) | 0.92 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.59% |
| Percentage Held By Institutions (Latest 13F Reports) | 96.70% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |